DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)

Information source: National Taiwan University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acute Renal Failure

Intervention: sustained low efficiency daily hemodiafiltration (SLEDD-f) (Device)

Phase: N/A

Status: Completed

Sponsored by: National Taiwan University Hospital

Official(s) and/or principal investigator(s):
Fe-Lin L Wu, MSCP, Ph.D., Principal Investigator, Affiliation: School of pharmacy, Graduate institute of clinical pharmacy, Department of Pharmacy of National Taiwan University Hospital, College of Medicine, National Taiwan University
Wen-Je Ko, MD, PhD, Principal Investigator, Affiliation: Department of Surgery, National Taiwan University Hospital, College of Medicine, National Taiwan University

Summary

1. Sustained low efficiency daily hemodiafiltration(SLEDD-f) is a kind of renal replacement therapy with high-flux dialyser membrane (helixone). 2. The pore size of helixone is larger than most antibiotics, and vancomycin is supposed to be removed during dialysis. 3. Our study wants to find the amount of vancomycin removed during SLEDD-f, and try to find the most appropriate dose regimen for this kind of patients.

Clinical Details

Official title: Pharmacokinetics and Dosing of Vancomycin in Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome:

The amount of vancomycin removed during one course of SLEDD-f

The pharmacokinetics and dosing regimen of vancomycin in patients on SLEDD-f.

Detailed description: Vancomycin is the most important antibiotic in the treatment of resistant G(+) bacteria infections. Close monitor of serum level is important to ensure its safety and effectiveness. So far there is not enough data to support the optimal dose regimen of vancomycin in patients on SLEDD-f. In this study, we draw blood levels between 2 doses of vancomycin to determine the pharmacokinetic parameters of vancomycin and fraction removed by SLEDD-f so as to determine the most appropriate dose regimen.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Acute renal failure of any cause

- Use SLEDD-f as renal replacement therapy

- Priscribe vancomycin for a known or suspected infection

Exclusion Criteria:

- None

Locations and Contacts

National Taiwan University Hospital, Taipei, Taiwan
Additional Information

Starting date: October 2008
Last updated: October 21, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017